文献速递免疫规划传染病防控与疫情报告

AVX/COVID-12「Patria」重组新城疫病毒疫苗单剂肌内或鼻内接种作为COVID-19异源加强针在墨西哥的安全性及免疫原性II期研究

Phase II study on the safety and immunogenicity of single-dose intramuscular or intranasal administration of the AVX/COVID-12 "Patria" recombinant Newcastle disease virus vaccine as a heterologous booster against COVID-19 in Mexico.
PubMed 文献 · Vaccine · 2024-11-10

在墨西哥开展的II期临床试验评估本地生产的AVX/COVID-12「Patria」疫苗作为异源加强针的安全性及免疫原性,受试者既往完成腺病毒载体、灭活病毒或mRNA疫苗接种且初始抗刺突IgG滴度低于1200 U/mL。肌内或鼻内接种均安全耐受,诱导针对武汉株及Alpha、Beta、Delta、Omicron(BA.2和BA.5)变异株的中和抗体显著(>2.5倍)升高,并增强干扰素-γ细胞应答。

要点

  • AVX/COVID-12「Patria」疫苗肌内或鼻内单剂加强接种均安全且耐受良好。
  • 疫苗诱导针对武汉株及Alpha、Beta、Delta、Omicron(BA.2和BA.5)的中和抗体显著(>2.5倍)升高。
  • 疫苗增强干扰素-γ细胞应答,显示稳健的多层面免疫反应。

核心结论

  • AVX/COVID-12「Patria」疫苗作为加强针,无论肌内还是鼻内途径,均安全且耐受良好,可扩展针对武汉-1株及多种变异株的免疫应答,并可能有助于扩大和维持群体免疫。

研究设计与样本

  • II期临床试验,评估本地生产的AVX/COVID-12「Patria」疫苗作为加强针的安全性及免疫原性,受试者既往完成腺病毒载体、灭活病毒或mRNA-based COVID-19疫苗接种且初始抗刺突IgG滴度低于1200 U/mL,分别经肌内或鼻内途径接种。

主要发现

  • 肌内和鼻内免疫接种AVX均安全且耐受良好。
  • 疫苗诱导针对祖先武汉株及关注变异株(Alpha、Beta、Delta、Omicron BA.2和BA.5)的中和抗体显著(>2.5倍)升高。
  • 疫苗增强干扰素-γ的细胞产生,显示稳健且多层面的免疫反应。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The global inequity in the distribution of COVID-19 vaccines underscores the urgent need for innovative and cost-effective vaccine technologies to address access disparities and implement local manufacturing capabilities. This is essential for achieving and sustaining widespread immunity, and for ensuring timely protection of vulnerable populations during future booster campaigns in lower- middle income countries (LMICs). METHODS: To address this need, we conducted a phase II clinical trial to evaluate the safety and immunogenicity of the locally manufactured AVX/COVID-12 "Patria" (AVX) vaccine as a booster dose. The vaccine was administered either intramuscularly (IM) or intranasally (IN) to participants who had previously completed a vaccination regimen for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) using adenoviral vector, inactivated virus, or mRNA-based vaccines. Participants with initial anti-spike IgG titers below 1,200 U/mL were included, allowing us to observe the booster effect induced by vaccination. RESULTS: Both IM and IN immunization with AVX were found to be safe and well-tolerated. The vaccine induced a significant (>2.5-fold) increase in neutralizing antibodies against the ancestral Wuhan strain and variants of concern (VOCs), including Alpha, Beta, Delta, and Omicron (BA.2 and BA.5). This immune response was further supported by increased cellular production of interferon-gamma (IFN-γ), demonstrating a robust and multifaceted immune reaction. CONCLUSIONS: The administration of AVX as a booster dose, whether through IM or IN routes, was safe and well-tolerated. The vaccine extended immune responses not only against the ancestral Wuhan-1 strain but also against various VOCs. Its ability to enhance preexisting immune responses suggests a potential contribution to expanding and sustaining herd immunity within the population.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. López-Macías C, Torres M, Armenta-Copca B, et al. Phase II study on the safety and immunogenicity of single-dose intramuscular or intranasal administration of the AVX/COVID-12 "Patria" recombinant Newcastle disease virus vaccine as a heterologous booster against COVID-19 in Mexico. Vaccine. 2024. PMID: 39527880. doi:10.1016/j.vaccine.2024.126511

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。